Celon Pharma Statistics

Total Valuation

Celon Pharma has a market cap or net worth of PLN 1.48 billion. The enterprise value is 1.37 billion.

Market Cap	1.48B
Enterprise Value	1.37B

Important Dates

The last earnings date was Wednesday, November 20, 2024.

Earnings Date	Nov 20, 2024
Ex-Dividend Date	Jun 27, 2024

Share Statistics

Celon Pharma has 53.86 million shares outstanding. The number of shares has increased by 0.04% in one year.

Current Share Class	n/a
Shares Outstanding	53.86M
Shares Change (YoY)	+0.04%
Shares Change (QoQ)	+4.79%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	11.87%
Float	23.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.78
PB Ratio	3.05
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-30.18
EV / Sales	6.64
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-119.25

Financial Position

The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.03.

Current Ratio	2.61
Quick Ratio	2.23
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-1.33
Interest Coverage	-17.73

Financial Efficiency

Return on equity (ROE) is -9.82% and return on invested capital (ROIC) is -5.77%.

Return on Equity (ROE)	-9.82%
Return on Assets (ROA)	-4.75%
Return on Capital (ROIC)	-5.77%
Revenue Per Employee	365,385
Profits Per Employee	-80,355
Employee Count	515
Asset Turnover	0.35
Inventory Turnover	2.21

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +89.89% in the last 52 weeks. The beta is 0.73, so Celon Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	+89.89%
50-Day Moving Average	27.94
200-Day Moving Average	21.37
Relative Strength Index (RSI)	49.79
Average Volume (20 Days)	58,630

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celon Pharma had revenue of PLN 206.81 million and -45.48 million in losses. Loss per share was -0.89.

Revenue	206.81M
Gross Profit	144.16M
Operating Income	-44.41M
Pretax Income	-38.69M
Net Income	-45.48M
EBITDA	-13.61M
EBIT	-44.41M
Loss Per Share	-0.89

Full Income Statement

Balance Sheet

The company has 121.09 million in cash and 15.25 million in debt, giving a net cash position of 105.84 million or 1.97 per share.

Cash & Cash Equivalents	121.09M
Total Debt	15.25M
Net Cash	105.84M
Net Cash Per Share	1.97
Equity (Book Value)	459.37M
Book Value Per Share	9.00
Working Capital	127.39M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.66 million and capital expenditures -17.17 million, giving a free cash flow of -11.51 million.

Operating Cash Flow	5.66M
Capital Expenditures	-17.17M
Free Cash Flow	-11.51M
FCF Per Share	-0.21

Full Cash Flow Statement

Margins

Gross margin is 69.71%, with operating and profit margins of -21.48% and -21.99%.

Gross Margin	69.71%
Operating Margin	-21.48%
Pretax Margin	-18.71%
Profit Margin	-21.99%
EBITDA Margin	-6.58%
EBIT Margin	-21.48%
FCF Margin	-5.57%

Dividends & Yields

This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 0.29%.

Dividend Per Share	0.08
Dividend Yield	0.29%
Dividend Growth (YoY)	-11.11%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.04%
Shareholder Yield	0.25%
Earnings Yield	-3.25%
FCF Yield	-0.78%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celon Pharma has an Altman Z-Score of 4.18.

Altman Z-Score	4.18
Piotroski F-Score	n/a